Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of swine diseases
3.2.1.2 Growing consumption of pork
3.2.1.3 Increasing government initiatives and support
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of vaccine development
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Inactivated vaccines
5.3 Live attenuated vaccines
5.4 Recombinant vaccines
5.5 Subunit vaccines
5.6 Toxoid vaccines
5.7 Other products
Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Porcine reproductive and respiratory syndrome (PRRS)
6.3 Porcine circovirus type 2 (PCV2)
6.4 Mycoplasma hyopneumoniae
6.5 Classical swine fever (CSF)
6.6 Swine influenza
6.7 Erysipelas
6.8 Foot-and-Mouth disease (FMD)
6.9 African swine fever (ASF)
6.10 Porcine parvovirus
6.11 Other disease types
Chapter 7 Market Estimates and Forecast, By End-user, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Veterinary hospitals & clinics
7.3 Swine farms
7.4 Research institutes
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Biogenesis Bago
9.2 Bioveta, a.s.
9.3 Boehringer Ingelheim International GmbH
9.4 Ceva Sante Animale
9.5 Elanco Animal Health Incorporated
9.6 HIPRA
9.7 Indian Immunologicals Limited
9.8 Merck & Co., Inc.
9.9 Phibro Animal Health Corporation
9.10 Vaxxinova
9.11 Virbac
9.12 Zoetis Inc.
